文献速递白血病

唐氏综合征急性淋巴细胞白血病预后与治疗相关毒性:JCCG ALL-B12 研究

Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12.
PubMed 文献 · Blood Adv · 2026-10-15

日本儿童癌症组 ALL-B12 全国前瞻性研究纳入 1804 例 ALL 患儿,其中 44 例为唐氏综合征(DS)ALL。DS-ALL 的 5 年无事件生存率和总生存率分别为 70.5% 和 81.8%,均低于非 DS-ALL 的 85.6% 和 94.6%(P < 0.001)。DS-ALL 治疗相关毒性更常见,包括黏膜炎、高血糖和肺部感染。

要点

  • DS-ALL 的 5 年 EFS 和 OS 分别为 70.5% 和 81.8%,低于非 DS-ALL(P < 0.001)。
  • DS-ALL 黏膜炎、高血糖、肺部感染发生率分别为 27.3%、25.0%、20.5%,均高于非 DS-ALL。
  • TP2 MRD ≥ 10^-4 的 DS-ALL 患者(n = 3)全部复发并在三年内死亡。

核心结论

  • DS-ALL 的生存率仍低于非 DS-ALL,且治疗相关毒性更常见,需优化治疗以降低复发和毒性。

研究设计与样本

  • 日本儿童癌症组 ALL-B12 全国前瞻性研究,采用风险适配治疗,共分析 1804 例 ALL 患者,其中 44 例为 DS-ALL。

主要发现

  • DS-ALL 的 5 年 EFS 为 70.5%,5 年 OS 为 81.8%,非 DS-ALL 分别为 85.6% 和 94.6%(P < 0.001)。
  • 生存差异在标危患者中最明显。
  • DS-ALL 有利遗传学特征较少,复发以孤立骨髓事件为主,无中枢神经系统复发。
  • CRLF2 重排在 43 例可评估 DS-ALL 中 15 例(34.9%)阳性;排除典型有利或不利亚型后(n = 36),CRLF2 重排阳性与阴性者 5 年 EFS 分别为 57.1% 和 81.8%(P = 0.300),5 年 OS 分别为 78.6% 和 86.4%(P = 0.331)。
  • DS-ALL 治疗相关毒性更常见:黏膜炎(27.3% vs. 7.1%)、高血糖(25.0% vs. 6.9%)、肺部感染(20.5% vs. 7.4%)。

临床怎么用

  • DS-ALL 治疗需关注高黏膜炎、高血糖和肺部感染风险,并加强 MRD 监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL). Although recent reports describe some improvement, survival in DS-ALL remains inferior to that of non-DS-ALL. This study evaluated the prognosis, relapse patterns, and treatment-related toxicities of DS-ALL in the Japan Children's Cancer Group ALL-B12 trial, a nationwide prospective study using risk-adapted therapy. A total of 1,804 patients, including 44 DS-ALL, were analyzed. Risk classification used standardized criteria. The 5-year event-free survival and overall survival in DS-ALL were 70.5% and 81.8%, respectively, lower than 85.6% and 94.6% in non-DS-ALL (P < 0.001). Survival differences were most pronounced in standard-risk patients. DS-ALL showed fewer favorable genetics and relapse patterns dominated by isolated bone marrow events, with no CNS relapse. CRLF2 rearrangement was assessable in 43 of 44 DS-ALL cases; 15 of 43 (34.9%) were positive. In an exploratory analysis excluding canonical favorable or unfavorable subtypes (n = 36), the 5-year EFS in DS-ALL with and without CRLF2 rearrangement were 57.1% and 81.8%, respectively (P = 0.300), and the corresponding 5-year OS were 78.6% and 86.4%, respectively (P = 0.331). Treatment-related toxicities were more frequent in DS-ALL, including mucositis (27.3% vs. 7.1%), hyperglycemia (25.0% vs. 6.9%), and pulmonary infections (20.5% vs. 7.4%). Among DS-ALL patients with TP2 MRD ≥ 10-4 (n = 3), all relapsed and died within three years. No treatment-related death was recorded after induction, but one death of undetermined cause occurred. These findings highlight the continuing need to optimize DS-ALL therapy to reduce relapse and toxicity. UMIN CT Registry (UMIN000009339) and JCT (jRCTs041180101).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yamamoto S, Kato M, Iijima-Yamashita Y, et al. Prognosis and treatment-related toxicities in Down syndrome acute lymphoblastic leukemia in JCCG ALL-B12. Blood Adv. 2026. PMID: 42879745. doi:10.1182/bloodadvances.2026021259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。